Table 4.
Multivariable Analysis of GvHD
| Grade II-IV aGvHD* | Grade III-IV aGvHD† | Any cGvHD‡ | Extensive cGvHD† | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| N | HR (95%CI) | P | HR (95%CI) | P | HR (95%CI) | P | HR (95%CI) | P | ||
| Age | <60 | 144 | Reference | 0.11 | Reference | 0.071 | Reference | 0.24 | Reference | 0.51 |
| ≥60 | 66 | 0.63(0.36,1.11) | 0.47(0.20,1.07) | 0.71(0.40,1.26) | 0.79(0.39,1.59) | |||||
| Sex | M | 122 | Reference | 0.33 | Reference | 0.52 | Reference | 0.69 | Reference | 0.12 |
| F | 88 | 0.81(0.52,1.25) | 0.79(0.37,1.65) | 1.10(0.68,1.77) | 1.57(0.89,2.76) | |||||
| Female donor to male recipient | No | 176 | Reference | 0.32 | Reference | 0.73 | Reference | 0.043 | Reference | 0.041 |
| Yes | 34 | 0.74(0.41,1.34) | 0.84(0.30,2.32) | 1.68(1.02,2.77) | 1.81(1.02,3.21) | |||||
| Disease Risk Index | Low | 31 | Reference | 0.50 | Reference | 0.50 | Reference | 0.81 | Reference | 0.38 |
| Intermediate | 81 | 0.88(0.47,1.66) | 1.35(0.38,4.82) | 0.87(0.47,1.62) | 1.64(0.72,3.72) | |||||
| High/Very high | 78 | 1.17(0.62,2.21) | 1.93(0.56,6.64) | 0.81(0.43,1.53) | 1.21(0.52,2.84) | |||||
| Conditioning regimen | MAC-TBI | 71 | Reference | 0.48 | Reference | 0.20 | Reference | 0.22 | Reference | 0.22 |
| MAC-Non- TBI | 18 | 1.51(0.64,3.59) | 0.85(0.09,8.14) | 0.64(0.27,1.55) | 0.72(0.28,1.85) | |||||
| RIC/NMA | 121 | 0.92(0.58,1.44) | 1.97(0.88,4.44) | 0.69(0.45,1.07) | 0.64(0.38,1.06) | |||||
| Donor type | Haploidentical | 172 | Reference | 0.22 | Reference | 0.43 | Reference | 0.41 | Reference | 0.64 |
| Mismatched unrelated | 38 | 1.41(0.82,2.45) | 1.39(0.61,3.17) | 1.26(0.73,2.20) | 1.17(0.61,2.23) | |||||
| ABO blood group compatibility | ABO Compatible | 139 | Reference | 0.70 | Reference | 0.76 | Reference | 0.64 | Reference | 0.95 |
| Minor | 32 | 1.19(0.66,2.14) | 0.55(0.17,1.78) | 1.38(0.76,2.49) | 0.96(0.47,1.95) | |||||
| Major | 24 | 1.17(0.60,2.29) | 1.02(0.34,3.05) | 1.13(0.60,2.12) | 1.08(0.49,2.36) | |||||
| Bidirectional | 15 | 1.50(0.75,3.00) | 1.17(0.34,4.01) | 1.45(0.65,3.21) | 1.31(0.50,3.44) | |||||
| Donor CMV serostatus | D+ | 143 | Reference | 0.31 | Reference | 0.40 | Reference | 0.069 | Reference | 0.100 |
| D− | 67 | 1.50(0.69,3.25) | 1.38(0.65,2.92) | 1.51(0.97,2.36) | 1.54(0.92,2.59) | |||||
| Recipient CMV serostatus | R+ | 177 | Reference | 0.31 | Reference | 0.67 | Reference | 0.36 | Reference | 0.56 |
| R− | 33 | 1.50(0.69,3.25) | 0.76(0.21,2.72) | 1.30(0.74,2.28) | 1.22(0.63,2.35) | |||||
| Graft source | Peripheral blood stem cells | 166 | Reference | 0.041 | Reference | 0.11 | Reference | 0.17 | Reference | 0.30 |
| Bone marrow | 44 | 0.49(0.25,0.97) | 0.36(0.10,1.27) | 0.58(0.26,1.27) | 0.58(0.21,1.60) | |||||
| Karnofsky Performance Status, % | ≥80 | 176 | Reference | 0.68 | Reference | 0.37 | Reference | 0.61 | Reference | 0.47 |
| <80 | 34 | 1.14(0.62,2.08) | 1.48(0.63,3.47) | 0.85(0.46,1.57) | 0.75(0.35,1.63) | |||||
| HCT-Comorbidity Index | 0–2 | 125 | Reference | 0.81 | Reference | 0.36 | Reference | 0.21 | Reference | 0.76 |
| ≥3 | 85 | 0.95(0.62,1.45) | 1.39(0.69,2.82) | 0.75(0.48,1.17) | 0.92(0.56,1.54) | |||||
| Tacrolimus initial dosing method | Flat | 131 | Reference | 0.23 | Reference | 0.58 | Reference | 0.074 | Reference | 0.36 |
| Weight-based | 79 | 0.76(0.48,1.19) | 0.81(0.38,1.71) | 0.65(0.41,1.04) | 0.78(0.46,1.32) | |||||
| Tacrolimus at initial steady state, ng/mL | <10 | 176 | Reference | 0.55 | Reference | 0.78 | Reference | 0.28 | Reference | 0.81 |
| ≥10 | 34 | 0.81(0.41,1.62) | 0.83(0.22,3.07) | 0.69(0.36,1.34) | 1.08(0.56,2.12) | |||||
*
Adjusted for Donor/Recipient CMV serostatus, Graft source, and Conditioning regimen
†
Adjusted for Graft source and Conditioning regimen
‡
Adjusted for Female donor to male recipient and Conditioning regimen